1. Home
  2. SEMR vs NVAX Comparison

SEMR vs NVAX Comparison

Compare SEMR & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo SEMrush Holdings Inc.

SEMR

SEMrush Holdings Inc.

HOLD

Current Price

$11.86

Market Cap

1.8B

Sector

Technology

ML Signal

HOLD

Logo Novavax Inc.

NVAX

Novavax Inc.

HOLD

Current Price

$6.82

Market Cap

1.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SEMR
NVAX
Founded
2008
1987
Country
United States
United States
Employees
1561
N/A
Industry
EDP Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.8B
1.1B
IPO Year
2021
1995

Fundamental Metrics

Financial Performance
Metric
SEMR
NVAX
Price
$11.86
$6.82
Analyst Decision
Buy
Hold
Analyst Count
7
8
Target Price
$13.80
$9.75
AVG Volume (30 Days)
1.2M
3.1M
Earning Date
11-05-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
2.07
Revenue
$428,627,000.00
$1,064,651,000.00
Revenue This Year
$20.35
$58.91
Revenue Next Year
$14.87
N/A
P/E Ratio
N/A
$3.30
Revenue Growth
19.87
20.27
52 Week Low
$6.56
$5.01
52 Week High
$18.74
$11.55

Technical Indicators

Market Signals
Indicator
SEMR
NVAX
Relative Strength Index (RSI) 79.90 47.95
Support Level $11.84 $6.36
Resistance Level $11.88 $7.00
Average True Range (ATR) 0.03 0.22
MACD -0.16 0.07
Stochastic Oscillator 25.00 66.67

Price Performance

Historical Comparison
SEMR
NVAX

About SEMR SEMrush Holdings Inc.

SEMrush Holdings Inc is engaged in the online visibility management software-as-a-service (SaaS) platform. Its platform utilizes data and intelligence at the core surrounded by AI-powered interconnected hubs focused on search engine optimization, paid advertising, social media management, local marketing, brand marketing, and content marketing Geographically, it generates revenues from the United States, the UK, and Others.

About NVAX Novavax Inc.

Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from the United States.

Share on Social Networks: